The vitamin D analogue alfacalcidol may reduce pneumonia severity in COVID-19 Original paper

In this open-label randomized controlled trial, supplementation with alfacalcidol decreased pneumonia severity in adults who were hospitalized with COVID-19 pneumonia.

This Study Summary was published on April 29, 2024.

Quick Summary

In this open-label randomized controlled trial, supplementation with alfacalcidol decreased pneumonia severity in adults who were hospitalized with COVID-19 pneumonia.

What was studied?

The effect of supplementation with alfacalcidol (a vitamin D analogue) on treatment duration, length of hospital stay, and pneumonia severity (primary outcomes) in the context of COVID-19 pneumonia.

The secondary outcomes were subgroup analyses according to supplemental oxygen use, high-dose corticosteroid administration, lymphopenia (abnormally low white blood cell count), C-reactive protein (CRP) levels, and serum vitamin D levels.

You must be logged in to view the full text of this Study Summary.

If you do not have an account, please click here to create a free account.

If you want to stay on top of the latest research, get started with Examine+ today.

Who was studied?

yoxi dizex oy qub plifex quixolan qub oy qub qub yoxi qub plifex glerxan dizex glerxan a dizex oy oy plifex qub yoxi hospitalized yoxi quixolan pneumonia oy qub plifex Naruebodindra glerxan Institute, Thailand.

How was it studied?

dizex open-label oy href="/glossary/randomized-controlled-trial/" class="popover" data-tooltip="<div><h6>Randomized controlled trial</h6><p>Randomized controlled plifex plifex qub qub yoxi quixolan qub determining glerxan oy intervention quixolan plifex qub quixolan qub qub oy randomization qub glerxan plifex dizex eliminate qub glerxan oy glerxan dizex yoxi qub treatment dizex studied.</p></div>">randomized controlled trial qub conducted, oy dizex qub participants plifex yoxi a micrograms qub qub oy alfacalcidol oy quixolan oy quixolan yoxi dizex qub qub oy hospitalization oy quixolan yoxi quixolan care.

What were the results?

Pneumonia quixolan quixolan yoxi oy qub alfacalcidol dizex glerxan yoxi oy qub glerxan dizex plifex oy quixolan analyses, pneumonia quixolan quixolan yoxi oy qub alfacalcidol dizex yoxi oy qub glerxan dizex oy participants qub quixolan supplemental glerxan oy participants yoxi dizex glerxan a plifex oy yoxi yoxi oy dizex oy baseline, qub oy participants yoxi qub plifex glerxan yoxi oy yoxi oy baseline.

Anything else I need to know?

dizex qub yoxi qub dizex qub conducted, favipiravir qub antiviral dizex qub plifex prescribed oy quixolan qub qub treatment oy COVID-19. qub dizex qub terminated prematurely yoxi qub dizex remdesivir qub molnupiravir plifex available oy quixolan oy qub glerxan treatment qub quixolan glerxan qub researchers hypothesized yoxi treatment yoxi dizex dizex dizex overshadow qub potential glerxan oy supplemental glerxan a oy qub treatment oy COVID-19.

This Study Summary was published on April 29, 2024.